Farmak, the leader in the domestic pharmaceutical market, has expanded the Lamicon antifungal line with a new drug product, Lamicon Dermgel. The new drug is produced in the form of a gel (15 g).
Lamicon Dermgel is an antifungal agent in the form of a gel with a broad spectrum of action and a short course of treatment. It helps to eliminate one of the major symptoms of fungal skin infection – itching.
The drug is recommended for the treatment of skin infections caused by dermatophytes (tinea corporis, tinea cruris, tinea pedis) and tinea versicolor.
The main feature of the new drug is its cooling effect and antipruritic action.
Now the Lamicon antifungal portfolio has three dosage forms for topical use: Lamicon cream, Lamicon spray, Lamicon Dermgel, and also Lamicon in tablet form.
The Australian market is considered well-regulated – at the same level as the US and the EU. Therefore, only few Ukrainian companies have the opportunity to supply their products to this country. The share of sales to Australia and Oceania in Ukrainian exports of pharmaceutical products is only 0.3%. “Today, Farmak is about the only […]
Every year, on the 2nd Thursday of November, many countries celebrate the World Quality Day. It was first held in 1990 at the initiative of the European Organization for Quality (an independent non-profit association that brings together 40 national quality organizations in European countries) with the support of the United Nations. Subsequently, the week th...
The 6th Conference of Farmak School of Young Scientists was held on 1 November 2018. 130 guests and employees of Farmak JSC attended the event; 26 reports were presented. This conference already enjoys popularity among students, young scientists, and post-graduate students. The School of Young Scientists is a platform for presenting scientific achievements a...